Related Experiment Video

Updated: Mar 25, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Emerging roles of Nrf2 signal in non-small cell lung cancer

Yijun Tian1, Qian Liu1, Xuelian He2

  • 1Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Building 303, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China.

Journal of Hematology & Oncology
|February 29, 2016
PubMed

Insights

The Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-like factor 2 (Keap1/Nrf2) pathway is frequently altered in squamous lung cancer. Dysregulation of this pathway negatively impacts non-small cell lung cancer patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide.
  • While treatments for lung adenocarcinoma have advanced, squamous lung cancer therapies are less effective.
  • The Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-like factor 2 (Keap1/Nrf2) pathway is frequently altered in squamous lung cancer.

Purpose of the Study:

  • To investigate the role and implications of the Keap1/Nrf2 pathway in non-small cell lung cancer.
  • To explore the associations between Nrf2 signaling and other cellular pathways.
  • To understand the prognostic significance of Nrf2 dysregulation in NSCLC patients.

Main Methods:

  • Review of recent studies on Keap1/Nrf2 pathway alterations in squamous lung cancer.
  • Analysis of Nrf2 signaling at DNA and protein levels in NSCLC patients.
  • Examination of emerging associations between Nrf2 and other pathways, including microRNA regulation.
  • Evaluation of preclinical data on Nrf2-activating or antagonizing agents.
  • Prognostic evaluation of Nrf2 signaling impact on patient survival.

Main Results:

  • Deregulated Nrf2 signaling is a common feature in NSCLC at both DNA and protein levels.
  • Emerging evidence links Nrf2 to other critical cellular pathways and microRNA regulation.
  • Preclinical studies show that agents targeting Nrf2 have varied effects during tumor initiation versus progression.
  • Elevated Nrf2 signaling is associated with a negative prognosis for NSCLC patients.

Conclusions:

  • The Keap1/Nrf2 pathway plays a significant role in non-small cell lung cancer, particularly squamous cell carcinoma.
  • Nrf2 dysregulation has a detrimental impact on patient survival.
  • Further research into the Keap1/Nrf2 pathway is warranted for developing novel NSCLC therapeutic strategies.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

510
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.3K
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

2.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K